

HER2 Inhibitors Market Players Focus On Partnerships To Boost Diverse Portfolios And Revenues

The Business Research Company's HER2 Inhibitors Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, April 4, 2022 /EINPresswire.com/ -- Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the market.

[HER2 inhibitors market overview](#) show

that there have been several partnerships in recent years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology.


Major players covered in the [global HER2 inhibitors industry](#) are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan and Biocon.

In August 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation acquired Trillium Therapeutics Inc for an undisclosed amount. This acquisition of Trillium will build a robust record of leadership in oncology, enhancing the hematology portfolio to enhance outcomes for people living with blood cancers worldwide. Trillium Therapeutics Inc is a Canada-based company that develops therapies for the treatment of cancer.

Read more on the Global HER2 Inhibitors Market Report

<https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report>

The rise in the number of breast cancer cases across the globe is likely to contribute to HER2 inhibitors market growth during the forecast period. According to the American Cancer Society,



there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed their treatment. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. According to the HER2 inhibitors market analysis, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years.

The global HER2 inhibitors market size is expected to grow from \$6.61 billion in 2021 to \$7.26 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The HER2 inhibitors market is expected to reach \$10.60 billion in 2026 at a CAGR of 9.9%.

TBRC's global HER2 inhibitors market report is segmented by treatment into monotherapy, combination therapy, by application into squamous cell carcinoma, adenocarcinoma, large cell carcinoma, breast cancer, others, by end-user into hospitals, clinics, others.

HER2 inhibitors global market report 2022 – by treatment (monotherapy, combination therapy), by application (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, breast cancer), by end user (hospitals, clinics) – market size, trends, and global forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a HER2 inhibitors market overview, forecast HER2 inhibitors market size and growth for the whole market, HER2 inhibitors market segments, geographies, HER2 inhibitors market trends, HER2 inhibitors market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global HER2 Inhibitors Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3396&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Breast Cancer Drugs Global Market Report 2022 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others: Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy), By Drug Type (Her2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor), By End User (Ambulatory, Hospitals, Clinics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report>

Cervical Cancer Drugs Global Market Report 2022 – By Cancer Type (Squamous Cell Cancer, Adenocarcinoma), By Drug Type (Avastin, Bevacizumb, Blemocin, Blenoxane), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/cervical-cancer-drugs-global-market-report>

Skin Cancer Drugs Global Market Report 2022 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By End Users (Hospitals, Cancer Research Centers, Clinics), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report>

Know More About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/567468723>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.